Phillips-Medisize, a Molex company and leader in the design, development, and manufacturing of drug delivery, diagnostic, and MedTech devices, collaborates with Subcuject, a global innovator of proprietary device platforms to introduce a wearable bolus injector based on osmosis to the market.
The new Wearable Osmotic Bolus Injector is designed to be a low-cost, patient-friendly, prefilled wearable injector for single-use. The product uses osmosis to generate the force required to complete a full injection cycle, requiring minimal components, which reduces development time and costs. it also eliminated the need for additional electronics or batteries, resulting in further cost reductions and a lower environmental impact.
Jesper Roested, CEO, Subcuject, said: “We are very pleased to collaborate with Phillips-Medisize to complete the development and manufacturing needed to bring our product innovation to pharma customers successfully. Together, we can address the emerging need for inexpensive, prefilled, and single-use injectors that can deliver drugs at about 1mL per minute.”
Paul Chaffin, Presiden, Phillips-Medisize, said: “Teaming with Subcuject to develop an affordable, versatile wearable injector leverages our combined strengths and global expertise in proprietary device platforms. We’re excited to develop the technology and pave the way toward commercialization.”
